A single nucleotide polymorphism in catalase is strongly associated with ovarian cancer survival

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Belotte, Jimmy ^a   Fletcher, Nicole M ^a   Saed, Mohammed G ^a   Abusamaan, Mohammed S ^a   Dyson, Gregory ^b   Diamond, Michael P ^c   Saed, Ghassan M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CATALASE; DNA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHI SQUARE TEST; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVITY; FEMALE; GENOTYPE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; OVARY CANCER; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; GENETICS; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PHYSIOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CATALASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84942880565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135739     Document Type: Article

References (67)

1. Erickson BK, Conner MG, Landen CN Jr (2013) The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 209: 409-414. doi: 10.1016/j.ajog.2013.04.019 PMID: 23583217
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi: 10. 3322/caac.21166 PMID: 23335087
3. Robella M, Vaira M, Marsanic P, Mellano A, Borsano A, Cinquegrana A, et al. (2014) Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Minerva Chir 69: 27-35. PMID: 24675244
4. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384: 1376-1388. doi: 10.1016/S0140-6736(13)62146-7 PMID: 24767708
5. Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP (2014) Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer. J Cancer 5: 25-30. doi: 10.7150/jca.7810 PMID: 24396495
6. NCI (2012) National Cancer Institute: PDQ Genetics of Breast and Ovarian Cancer. Available: http:// wwwcancergov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page2.
7. Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, et al. (2009) Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 3: 171-181. doi: 10.1016/j.molonc.2009.01. 008 PMID: 19383379
8. Singh M, Singh P, Juneja PK, Singh S, Kaur T (2011) SNP-SNP interactions within APOE gene influence plasma lipids in postmenopausal osteoporosis. Rheumatol Int 31: 421-423. doi: 10.1007/ s00296-010-1449-7 PMID: 20340021
9. Hamosh A, King TM, Rosenstein BJ, Corey M, Levison H, Durie P, et al. (1992) Cystic fibrosis patients bearing both the common missense mutation Gly-Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus. Am J Hum Genet 51: 245-250. PMID: 1379413
10. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52: 349-355. PMID: 11678778
11. Lee CR (2004) CYP2C9 genotype as a predictor of drug disposition in humans. Methods Find Exp Clin Pharmacol 26: 463-472. PMID: 15349140
12. Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y (2006) Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett 234: 73-80. PMID: 16303243
13. Erichsen HC, Chanock SJ (2004) SNPs in cancer research and treatment. Br J Cancer 90: 747-751. PMID: 14970847
14. Savas S, Schmidt S, Jarjanazi H, Ozcelik H (2006) Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: potential breast cancer risk alleles and their distribution across human populations. Hum Genomics 2: 287-296. PMID: 16595073
15. Klaunig JE, Kamendulis LM, Hocevar BA (2010) Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38: 96-109. doi: 10.1177/0192623309356453 PMID: 20019356
16. Jiang Z, Fletcher NM, Ali-Fehmi R, Diamond MP, Abu-Soud HM, Munkarah AR, et al. (2011) Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. Gynecol Oncol 122: 418-423. doi: 10.1016/j.ygyno.2011.04.051 PMID: 21620448
17. Saed GM, Fletcher NM, Jiang ZL, Abu-Soud HM, Diamond MP (2011) Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress. Reprod Sci 18: 1253-1261. doi: 10.1177/1933719111411731 PMID: 21701041
18. Ahn J, Ambrosone CB, Kanetsky PA, Tian C, Lehman TA, Kropp S, et al. (2006) Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer. Clin Cancer Res 12: 7063-7070. PMID: 17145829
19. Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, et al. (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 65: 1105-1111. PMID: 15705913
20. Crawford A, Fassett RG, Geraghty DP, Kunde DA, Ball MJ, Robertson IK, et al. (2012) Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene 501: 89-103. doi: 10.1016/j.gene.2012.04.011 PMID: 22525041
21. Didziapetriene J, Bublevic J, Smailyte G, Kazbariene B, Stukas R (2014) Significance of blood serum catalase activity and malondialdehyde level for survival prognosis of ovarian cancer patients. Medicina (Kaunas) 50: 204-208.
22. Janicka A, Szymanska-Pasternak J, Bober J (2013) [Polymorphisms in the oxidative stress-related genes and cancer risk]. Ann Acad Med Stetin 59: 18-28.
23. Li Y, Ambrosone CB, McCullough MJ, Ahn J, Stevens VL, Thun MJ, et al. (2009) Oxidative stressrelated genotypes, fruit and vegetable consumption and breast cancer risk. Carcinogenesis 30: 777-784. doi: 10.1093/carcin/bgp053 PMID: 19255063
24. Saadat M, Saadat S (2014) Genetic Polymorphism of CAT C-262 T and Susceptibility to Breast Cancer, a Case-Control Study and Meta-Analysis of the Literatures. Pathol Oncol Res.
25. Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, et al. (2013) Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients-potential differential effects by radiotherapy? Breast 22: 817-823. doi: 10.1016/j.breast.2013.02.008 PMID: 23489758
26. Tsai SM, Wu SH, Hou MF, Chen YL, Ma H, Tsai LY (2012) Oxidative stress-related enzyme gene polymorphisms and susceptibility to breast cancer in non-smoking, non-alcohol-consuming Taiwanese women: a case-control study. Ann Clin Biochem 49: 152-158. doi: 10.1258/acb.2011.011098 PMID: 22130631
27. Kaplun L, Fridman AL, Chen W, Levin NK, Ahsan S, Petrucelli N, et al. (2012) Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families. Biomark Insights 7: 151-157. doi: 10.4137/BMI.S10815 PMID: 23300341
28. Senthil K, Aranganathan S, Nalini N (2004) Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta 339: 27-32. PMID: 14687890
29. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P (2004) Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 53: 209-219. PMID: 14610616
30. Behrman HR, Kodaman PH, Preston SL, Gao S (2001) Oxidative stress and the ovary. J Soc Gynecol Investig 8: S40-42. PMID: 11223371
31. Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA, et al. (2011) Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer. Cancer Biomark 10: 267-275. doi: 10.3233/CBM-2012-0255 PMID: 22820082
32. Saed GM, Ali-Fehmi R, Jiang ZL, Fletcher NM, Diamond MP, Abu-Soud HM, et al. (2010) Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol Oncol 116: 276-281. doi: 10.1016/j.ygyno.2009.11.004 PMID: 19962178
33. Malone JM, Saed GM, Diamond MP, Sokol RJ, Munkarah AR (2006) The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. Am J Obstet Gynecol 194: 1110-1116; discussion 1116-1118. PMID: 16580304
34. Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, et al. (2013) Association of myeloperoxidase with ovarian cancer. Tumour Biol.
35. Abu-Soud HM, Hazen SL (2000) Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 275: 37524-37532. PMID: 11090610
36. Abu-Soud HM, Hazen SL (2000) Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem 275: 5425-5430. PMID: 10681518
37. Becquemont L (2009) Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10: 961-969. doi: 10.2217/pgs.09.37 PMID: 19530963
38. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C (2010) Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 9: 224-228. doi: 10.3816/CCC.2010.n.033 PMID: 20920994
39. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, et al. (2009) Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10: 579-599. doi: 10.2217/pgs.09.7 PMID: 19374516
40. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB (2008) Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 18: 11-24. PMID: 18216718
41. Huser V, Cimino JJ (2013) Providing pharmacogenomics clinical decision support using whole genome sequencing data as input. AMIA Jt Summits Transl Sci Proc 2013: 81. PMID: 24303303
42. Lee SY, McLeod HL (2011) Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J Pathol 223: 15-27. doi: 10.1002/path.2766 PMID: 20818641
43. Rotimi CN, Jorde LB (2010) Ancestry and disease in the age of genomic medicine. N Engl J Med 363: 1551-1558. doi: 10.1056/NEJMra0911564 PMID: 20942671
44. Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, et al. (2010) Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11: 1149-1167. doi: 10.2217/pgs.10.97 PMID: 20712531
45. Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, Churchill E, et al. (2013) Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One 8: e57639. doi: 10.1371/journal.pone. 0057639 PMID: 23536766
46. Klaunig JE, Wang Z, Pu X, Zhou S (2011) Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol 254: 86-99. doi: 10.1016/j.taap.2009.11.028 PMID: 21296097
47. Prat J, Ribe A, Gallardo A (2005) Hereditary ovarian cancer. Hum Pathol 36: 861-870. PMID: 16112002
48. Petrucelli N, Daly MB, Feldman GL (2010) Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 12: 245-259. doi: 10.1097/GIM.0b013e3181d38f2f PMID: 20216074
49. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, et al. (2008) Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 123: 380-388. doi: 10.1002/ijc.23448 PMID: 18431743
50. Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Phelan CM, Anderson S, et al. (2009) Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 18: 935-944. doi: 10.1158/1055-9965.EPI-08-0860 PMID: 19258477
51. Notaridou M, Quaye L, Dafou D, Jones C, Song H, Hogdall E, et al. (2011) Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer 128: 2063-2074. doi: 10.1002/ijc.25554 PMID: 20635389
52. Forsberg L, Lyrenas L, de Faire U, Morgenstern R (2001) A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 30: 500-505. PMID: 11182520
53. Quick SK, Shields PG, Nie J, Platek ME, McCann SE, Hutson AD, et al. (2008) Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 17: 1082-1087. doi: 10.1158/1055-9965.EPI-07-2755 PMID: 18483329
54. Cheng JC, Klausen C, Leung PC (2010) Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells. Mol Endocrinol 24: 1569-1580. doi: 10.1210/me.2010-0034 PMID: 20610539
55. Cheng JC, Klausen C, Leung PC (2013) Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett 329: 197-206. doi: 10.1016/j.canlet.2012.10.029 PMID: 23142284
56. Huntsman DG, Caldas C (1998) Assignment1 of the E-cadherin gene (CDH1) to chromosome 16q22.1 by radiation hybrid mapping. Cytogenet Cell Genet 83: 82-83. PMID: 9925936
57. Semb H, Christofori G (1998) The tumor-suppressor function of E-cadherin. Am J Hum Genet 63: 1588-1593. PMID: 9837810
58. Wong AS, Gumbiner BM (2003) Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 161: 1191-1203. PMID: 12810698
59. Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, et al. (2002) Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer 102: 530-535. PMID: 12432558
60. Izakovicova Holla L, Kankova K, Znojil V (2009) Haplotype analysis of the NADPH oxidase p22 phox gene in patients with bronchial asthma. Int Arch Allergy Immunol 148: 73-80. doi: 10.1159/000151508 PMID: 18716406
61. He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J (2009) A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 113: 585-594. doi: 10.1007/s10549-008-9962-z PMID: 18340529
62. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11: 570-579. PMID: 8445433
63. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214. PMID: 7459811
64. Gill S, Sargent D (2006) End points for adjuvant therapy trials: has the time come to accept diseasefree survival as a surrogate end point for overall survival? Oncologist 11: 624-629. PMID: 16794241
65. Stewart DJ (2012) Before we throw out progression-free survival as a valid end point. J Clin Oncol 30: 3426-3427. doi: 10.1200/JCO.2012.44.1220 PMID: 22826275
66. Booth CM, Eisenhauer EA (2012) Progression-free survival: meaningful or simply measurable? J Clin Oncol 30: 1030-1033. doi: 10.1200/JCO.2011.38.7571 PMID: 22370321
67. Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101: 1642-1649. doi: 10.1093/jnci/djp369 PMID: 19903805